ChabioTech Receives Approval to Change Clinical Trials Phase 1 and 2a for Degenerative Disc Disease Treatment

[Asia Economy Reporter Minji Lee] Cha Biotech announced on the 15th that the Ministry of Food and Drug Safety approved a change in the clinical phase 1 and 2a trial plan evaluating the safety and efficacy of 'CordSTEM-DD' for chronic low back pain patients caused by degenerative lumbar intervertebral discs.